Trials / Completed
CompletedNCT01970540
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination With Doxorubicin in Non-heavily Pretreated Patients With Selected Advanced Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- PharmaMar · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with doxorubicin, to characterize the safety profile and feasibility of this combination, to characterize the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity,to explore the feasibility, safety and efficacy of a potential improvable dose of this combination in selected tumor types \[i.e. small cell lung cancer (SCLC) and endometrial cáncer\] and to evaluate the pharmacogenomics (PGx) in tumor samples of patients exposed to PM01183 and doxorubicin at the RD in order to assess potential markers of response and/or resistance.
Detailed description
The study has currently met its primary end point and is now recruiting patients to be treated at the RD expansion cohort of selected tumor types, specifically: endometrial adenocarcinomas, neuroendocrine tumors, and small-cell lung cancer (SCLC).
Conditions
- Endometrial Adenocarcinomas
- Neuroendocrine Tumors
- Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lurbinectedin (PM01183) | lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials. |
| DRUG | Doxorubicin | Commercially available presentations of vials containing doxorubicin will be provided as appropriate. |
Timeline
- Start date
- 2011-05-25
- Primary completion
- 2017-08-09
- Completion
- 2017-08-09
- First posted
- 2013-10-28
- Last updated
- 2020-03-09
- Results posted
- 2020-03-09
Locations
7 sites across 2 countries: Spain, United Kingdom
Source: ClinicalTrials.gov record NCT01970540. Inclusion in this directory is not an endorsement.